Karolinska Development’s portfolio company Aprea Therapeutics (Aprea) continues to show a strong momentum and delivers highly positive news. The company reports that the FDA has granted Orphan Drug and Fast Track designation to the lead candidate (APR-246) in TP53 mutated (Myelodysplastic Syndromes) MDS.